Progressive Brain Change in Schizophrenia: A Prospective Longitudinal Study of First-Episode Schizophrenia

Psychiatric Iowa Neuroimaging Consortium, The University of Iowa Carver College of Medicine, Iowa City, Iowa 52242, USA.
Biological psychiatry (Impact Factor: 10.26). 07/2011; 70(7):672-9. DOI: 10.1016/j.biopsych.2011.05.017
Source: PubMed


Schizophrenia has a characteristic onset during adolescence or young adulthood but also tends to persist throughout life. Structural magnetic resonance studies indicate that brain abnormalities are present at onset, but longitudinal studies to assess neuroprogression have been limited by small samples and short or infrequent follow-up intervals.
The Iowa Longitudinal Study is a prospective study of 542 first-episode patients who have been followed up to 18 years. In this report, we focus on those patients (n = 202) and control subjects (n = 125) for whom we have adequate structural magnetic resonance data (n = 952 scans) to provide a relatively definitive determination of whether progressive brain change occurs over a time interval of up to 15 years after intake.
A repeated-measures analysis showed significant age-by-group interaction main effects that represent a significant decrease in multiple gray matter regions (total cerebral, frontal, thalamus), multiple white matter regions (total cerebral, frontal, temporal, parietal), and a corresponding increase in cerebrospinal fluid (lateral ventricles and frontal, temporal, and parietal sulci). These changes were most severe during the early years after onset. They occur at severe levels only in a subset of patients. They are correlated with cognitive impairment but only weakly with other clinical measures.
Progressive brain change occurs in schizophrenia, affects both gray matter and white matter, is most severe during the early stages of the illness, and occurs only in a subset of patients. Measuring severity of progressive brain change offers a promising new avenue for phenotype definition in genetic studies of schizophrenia.

Full-text preview

Available from:
  • Source
    • "Schizophrenia is a devastating and disabling neuropsychiatric disorder. The neural mechanisms of this disorder have been attributed to structural and functional abnormalities of the brain [1] [2] [3] [4] [5]. Schizophrenia patients have exhibited functional changes in both task-evoked activation and spontaneous brain activity [6] [7]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Altered spontaneous brain activity as measured by ALFF, fALFF, and ReHo has been reported in schizophrenia, but no consensus has been reached on alternations of these indexes in the disorder. We aimed to clarify the regional alterations in ALFF, fALFF, and ReHo in schizophrenia using a meta-analysis and a large-sample validation. A meta-analysis of activation likelihood estimation was conducted based on the abnormal foci of ten studies. A large sample of 86 schizophrenia patients and 89 healthy controls was compared to verify the results of the meta-analysis. Meta-analysis demonstrated that the alternations in ALFF and ReHo had similar distribution in schizophrenia patients. The foci with decreased ALFF/fALFF and ReHo in schizophrenia were mainly located in the somatosensory cortex, posterior parietal cortex, and occipital cortex; however, foci with increased ALFF/fALFF and ReHo were mainly located in the bilateral striatum, medial temporal cortex, and medial prefrontal cortex. The large-sample study showed consistent findings with the meta-analysis. These findings may expound the pathophysiological hypothesis and guide future research.
    07/2015; 2015:1-11. DOI:10.1155/2015/204628
  • Source
    • "The change score of clinical assessments were calculated by subtracting the scores of clinical assessments at follow-up from the scores of clinical assessments at baseline. We also recorded time in hospital during the interscan interval as a measure of illness severity in patients with schizophrenia, reasoning that hospitalization time was a proxy measure of relapse duration, which has been associated with volume loss in schizophrenia (Andreasen et al., 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Progressive brain volume loss in schizophrenia has been reported in previous studies but its cause and regional distribution remains unclear. We investigated progressive regional brain reductions in schizophrenia and correlations with potential mediators. Participants were drawn from the Northern Finland Birth Cohort 1966. A total of 33 schizophrenia individuals and 71 controls were MRI scanned at baseline (mean age=34.7, SD=0.77) and at follow-up (mean age=43.4, SD=0.44). Regional brain change differences and associations with clinical mediators were examined using FSL voxelwise SIENA. Schizophrenia cases exhibited greater progressive brain reductions than controls, mainly in the frontal and temporal lobes. The degree of periventricular brain volume reductions were predicted by antipsychotic medication exposure at the fourth ventricular edge and by the number of days in hospital between the scans (a proxy measure of relapse duration) at the thalamic ventricular border. Decline in social and occupational functioning was associated with right supramarginal gyrus reduction. Our findings are consistent with the possibility that antipsychotic medication exposure and time spent in relapse partially explain progressive brain reductions in schizophrenia. However, residual confounding could also account for the findings and caution must be applied before drawing causal inferences from associations demonstrated in observational studies of modest size. Less progressive brain volume loss in schizophrenia may indicate better preserved social and occupational functions. Copyright © 2015. Published by Elsevier B.V.
    Schizophrenia Research 07/2015; 70(1). DOI:10.1016/j.schres.2015.06.016 · 3.92 Impact Factor
  • Source
    • "There is evidence of volume reduction compared with healthy subjects in both the gray matter (GM) and white matter (WM) of many brain regions, but in particular in the temporal and frontal lobes (Highley et al., 1999; Selemon et al., 2002; Honea et al., 2005; Vita et al., 2012; Haijma et al., 2013). Reduced brain volumes are seen in people with firstepisode schizophrenia, suggesting that the changes that lead to this observation may be neurodevelopmental in origin (Asami et al., 2012; Rais et al., 2012; Vita et al., 2012), but greater tissue loss over time has been observed in patients with established schizophrenia compared with healthy subjects, suggesting that there are also progressive brain changes throughout the disease (Andreasen et al., 2011; Olabi et al., 2011). These studies all demonstrate the structural heterogeneity between subjects and regions and over time, however, which may be related to some extent to the diversity of symptoms patients experience and their individual responses to antipsychotic medication. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Approximately one third of people with schizophrenia are treatment-resistant and some do not achieve remission with clozapine, the gold-standard antipsychotic medication for treatment-resistant schizophrenia. This study compared global and regional brain volumes between treatment-responders and treatment-resistant patients with schizophrenia, including a group of patients who were clozapine-resistant. T1-weighted brain MRI were obtained on a 3T scanner in 20 controls and 52 people with schizophrenia who were selected based on their symptomatic response to antipsychotic medication: 18 responding well to first-line atypical antipsychotics (FLR), 19 treatment-resistant but responsive to clozapine monotherapy (TR), and 15 ultra-treatment-resistant who did not respond to clozapine (UTR). Treatment groups were matched for disease duration and current psychopathology. SIENAX and FSL-VBM were used to investigate differences in global brain, grey matter (GM), white matter (WM), ventricular CSF volumes, and regional GM volumes. GM volume was significantly reduced in TR and UTR groups compared with controls and the FLR group (p<0.05). Significantly reduced GM volume was observed in TR patients compared with FLRs in the superior, middle and inferior temporal gyri, pre/post-central gyri, middle and superior frontal gyri, supramarginal gyrus and lateral occipital cortex. UTR patients showed reduced GM compared with FLRs in the right parietal operculum and left cerebellum. No significant volume differences were observed between TR and UTR groups. These differences are unlikely to be solely due to medication effects and reduced GM volume in treatment-resistant schizophrenia may represent an accelerated disease course or a different underlying pathology. © The Author 2014. Published by Oxford University Press on behalf of CINP.
    The International Journal of Neuropsychopharmacology 02/2015; 18(7). DOI:10.1093/ijnp/pyv016 · 4.01 Impact Factor
Show more